About Prexton Therapeutics
Prexton Therapeutics develops foslevodopa and fosinecapam mGluR4 PAM therapies targeting motor complications in Parkinson disease through novel non-dopaminergic mechanisms.
📍 Location & Offices
📋 Request a Quote
Send your requirements directly to Prexton Therapeutics. Response typically within 48 hours.
Company Info
TypePrivate
Founded2014
Employees30
Revenue$4M
HQUtrecht, Netherlands
